Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favourable safety profile in difficult-to-treat scalp and genital psoriasis ...

In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear ...

Home remedies for yeast infections may include garlic, yogurt, probiotics, boric acid, baking soda, and more, but it's ...

The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial ...

As part of BellaNaija’s #StopHPVForHer campaign, Pharm. Aishat Mohammed of Medicaid is confronting myths about the HPV ...

Get exclusive access to the Vancouver Sun ePaper, an electronic replica of the print edition that you can share, download and ...

Menopause brings hormonal shifts, increasing bone loss risk. Postmenopausal osteoporosis, a silent disease, weakens bones due ...

Johnson & Johnson (JNJ) released new 52-week Phase 3 results from the ICONIC-TOTAL study evaluating icotrokinra, a first-in-class oral peptide that selectively blocks ...

Mental health issues associated with menopause are frequently ignored. Yet during this transition period, symptoms of ...

As the federal and state governments focus their attention on malaria, TB, and HIV control, thousands of Nigerians, including ...